Journal Article

CT-230: Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study

  • Palomba M
  • Schuster S
  • Karmali R
  • et al.
Clinical Lymphoma Myeloma and Leukemia (2025) 25 S1006-S1007
DOI: 10.1016/s2152-2650(25)02763-6
N/ACitations
Citations of this article
3Readers
Mendeley users who have this article in their library.
Get full text

Cite

CITATION STYLE

APA

Palomba, M. L., Schuster, S. J., Karmali, R., Skarbnik, A. P., Abramson, J. S., Ardeshna, K., … Morschhauser, F. (2025). CT-230: Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study. Clinical Lymphoma Myeloma and Leukemia, 25, S1006–S1007. https://doi.org/10.1016/s2152-2650(25)02763-6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free